Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib

Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the liter...

Descripción completa

Detalles Bibliográficos
Autores principales: Gravbrot, Nicholas, Sundararajan, Srinath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800898/
https://www.ncbi.nlm.nih.gov/pubmed/31687241
http://dx.doi.org/10.1155/2019/3051945
_version_ 1783460491862999040
author Gravbrot, Nicholas
Sundararajan, Srinath
author_facet Gravbrot, Nicholas
Sundararajan, Srinath
author_sort Gravbrot, Nicholas
collection PubMed
description Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the literature. Here, we report the first case of severe hepatic injury associated with encorafenib/binimetinib in a 58-year-old gentleman requiring admission and extensive workup. He was successfully treated by withdrawing the combination therapy, and liver function returned to normal range.
format Online
Article
Text
id pubmed-6800898
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68008982019-11-04 Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib Gravbrot, Nicholas Sundararajan, Srinath Case Rep Oncol Med Case Report Encorafenib/binimetinib is a new combination BRAF/MEK inhibitor used in the treatment of advanced or metastatic BRAFV600-mutant melanoma. Though generally tolerated well, mild to moderate aminotransferase elevations are common. However, significant liver injury has not been demonstrated in the literature. Here, we report the first case of severe hepatic injury associated with encorafenib/binimetinib in a 58-year-old gentleman requiring admission and extensive workup. He was successfully treated by withdrawing the combination therapy, and liver function returned to normal range. Hindawi 2019-10-07 /pmc/articles/PMC6800898/ /pubmed/31687241 http://dx.doi.org/10.1155/2019/3051945 Text en Copyright © 2019 Nicholas Gravbrot and Srinath Sundararajan. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Gravbrot, Nicholas
Sundararajan, Srinath
Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
title Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
title_full Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
title_fullStr Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
title_full_unstemmed Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
title_short Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
title_sort severe drug-induced liver injury from combination encorafenib/binimetinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800898/
https://www.ncbi.nlm.nih.gov/pubmed/31687241
http://dx.doi.org/10.1155/2019/3051945
work_keys_str_mv AT gravbrotnicholas severedruginducedliverinjuryfromcombinationencorafenibbinimetinib
AT sundararajansrinath severedruginducedliverinjuryfromcombinationencorafenibbinimetinib

Ejemplares similares